• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恩格列净致皮肤结节性多动脉炎 1 例报告

Case Report of Empagliflozin-Induced Cutaneous Polyarteritis Nodosa.

机构信息

1 Division of Dermatology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada.

2 Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada.

出版信息

J Cutan Med Surg. 2018 Sep/Oct;22(5):516-518. doi: 10.1177/1203475418760457. Epub 2018 Feb 18.

DOI:10.1177/1203475418760457
PMID:29457486
Abstract

Polyarteritis nodosa (PAN) is a rare vasculitis affecting medium-sized vessels. Cutaneous PAN is a clinical variant, and we report the first case of empagliflozin-induced cutaneous PAN in a 69-year-old man. After starting empagliflozin, the patient presented with tender subcutaneous nodules on his legs, which showed a medium-sized vessel vasculitis on histopathology. Upon cessation of this medication, he had full resolution of these nodules. This case illustrates that empagliflozin can induce cutaneous PAN, and further attention to this medication's association with cutaneous PAN is warranted.

摘要

结节性多动脉炎(PAN)是一种罕见的影响中等大小血管的血管炎。皮肤型 PAN 是一种临床变异型,我们报告了首例恩格列净引起的 69 岁男性皮肤型 PAN 病例。开始使用恩格列净后,该患者腿部出现触痛性皮下结节,组织病理学显示中等大小血管血管炎。停止使用该药后,这些结节完全消退。该病例表明,恩格列净可引起皮肤型 PAN,需要进一步关注该药与皮肤型 PAN 的关联性。

相似文献

1
Case Report of Empagliflozin-Induced Cutaneous Polyarteritis Nodosa.恩格列净致皮肤结节性多动脉炎 1 例报告
J Cutan Med Surg. 2018 Sep/Oct;22(5):516-518. doi: 10.1177/1203475418760457. Epub 2018 Feb 18.
2
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.恩格列净治疗2型糖尿病合并外周动脉疾病患者的心血管结局及安全性:EMPA-REG OUTCOME研究的亚组分析
Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.
3
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?心力衰竭中利尿剂抵抗:恩格列净有作用吗?
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
4
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.恩格列净与急性心力衰竭后再住院及死亡风险降低相关。
Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339.
5
[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].[SGLT2抑制剂治疗所致严重非典型酮症酸中毒:两例报告]
Internist (Berl). 2018 Mar;59(3):282-287. doi: 10.1007/s00108-017-0316-y.
6
Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.恩格列净相关的正常血糖性糖尿病酮症酸中毒
Am J Ther. 2018 Nov/Dec;25(6):e740-e741. doi: 10.1097/MJT.0000000000000752.
7
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.恩格列净对2型糖尿病合并已确诊心血管疾病患者预期寿命的长期益处。
Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810.
8
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度?临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
9
Cutaneous polyarteritis nodosa sine nodosa.皮肤型结节性多动脉炎。
J Cutan Med Surg. 2014 Nov;18(6):420-3. doi: 10.2310/7750.2014.13165.
10
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.恩格列净对 EMPA-REG OUTCOME® 试验中心力衰竭风险谱中心血管死亡和心力衰竭住院风险的影响。
Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511.

引用本文的文献

1
SGLT-2 inhibitors: new horizons for rheumatologists.SGLT-2 抑制剂:风湿病学家的新视野。
Curr Opin Rheumatol. 2024 Sep 1;36(5):351-359. doi: 10.1097/BOR.0000000000001030. Epub 2024 Jul 24.
2
Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview ofits Chemistry, Pharmacology, and Toxicology.恩格列净钠:钠-葡萄糖协同转运蛋白 2 抑制剂的概述——其化学、药理学和毒理学特性。
Curr Diabetes Rev. 2024;20(10):e230124226010. doi: 10.2174/0115733998271026231127051545.
3
A Spotlight on Drug-Induced Vasculitis.药物性血管炎聚焦
Curr Rheumatol Rep. 2022 Nov;24(11):323-336. doi: 10.1007/s11926-022-01088-0. Epub 2022 Sep 21.